AdaptHealth (AHCO) expects "minimal impact" from tariffs in 2025, and the diabetes segment "appears to be turning a corner," RBC Capital Markets said in a report.
Discussions with AdaptHealth's "manufacturing partners have not indicated that tariffs are likely to pose a significant issue," the report said.
The diabetes segment turnaround seems to be "underway with new starts improving sequentially in two consecutive quarters," and the resupply attrition rate was the lowest in two years, RBC said.
AdaptHealth's Q1 sleep segment revenue fell 3% as setups came in "slightly below management expectations" at 113,000, RBC said.
Management is launching a "scheduling system to reduce friction for new setups, alongside other strategic tools to combat the competitive environment," the report said.
RBC cut its price target on AdaptHealth stock to $13 from $14, citing "industry multiple compression," and reiterated its outperform rating.
Price: 8.51, Change: +0.28, Percent Change: +3.34
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.